MIAMI (PRWEB) October 13, 2014

Global Stem Cells Group, Inc. has launched a new corporate website (http://www.stemcellsgroup.com) designed to better highlight its six stem cell-related operating companies and provide up-to-date information on upcoming conferences, corporate news, stem cell research findings and more.

The website offers detailed information on each stem cell division including:

For more information about any of the Global Stem Cells Group operating companies, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

###

Read more from the original source:
Global Stem Cells Group Launches New Corporate Website

Beverly Hills, California (PRWEB) October 13, 2014

Top Beverly Hills and LA orthopedic doctor, Dr. Raj, is now offering platelet rich plasma therapy for sports injuries and all types of degenerative arthritis. The treatment option has recently been added to Dr. Raj's regenerative medicine therapies such as bone marrow derived stem cell procedures and amniotic derived stem cell therapies. Call (310) 247-0466 for more information and scheduling.

Platelet Rich Plasma Therapy, known as PRP for short, has been increasing in popularity due to the success shown in several research studies. There was a recent study out of HSS showing amazing outcomes for degenerative knee arthritis, with preservation of cartilage and significant pain relief. Results with rotator cuff tendonitis, tennis elbow, plantar fasciitis and knee/achilles tendonitis have also been excellent as well.

Athletes in all types of sports have benefited from PRP therapy including golf, tennis, basketball, football, baseball and more. Whether or not an athlete is professional or amateur, the PRP treatment can be instrumental in helping patients avoid surgery and get back on the field quickly.

PRP therapy at Beverly Hills Orthopedic Institute involves an outpatient procedure that begins with a simple blood draw from the patient's arm of approximately 30 to 60 millileters. The blood is placed into a centrifuge and spun rapidly for 15-20 minutes. The platelets become concentrated in the middle layer, and this is what is utilized for the platelet rich plasma therapy in Beverly Hills.

The PRP therapy is injected under sterile conditions into the painful area. Results are typically seen over the ensuing weeks. Along with the PRP treatment, Dr. Raj also offers bone marrow and amniotic stem cell therapy. Typically, the best regenerative medicine therapy option is decided upon in conjunction with the patient.

Dr. Raj is a Double Board Certified Beverly Hills and Los Angeles orthopedic surgeon, who is also an ABC News Medical Correspondent along with a WebMD expert. For those interested in PRP and stem cell therapy Beverly Hills trusts, call (310) 247-0466.

Excerpt from:
Top Beverly Hills Orthopedic Doctor, Dr. Raj, Now Offering Platelet Rich Plasma Therapy for All Sports Injuries and ...

MADISON Winning the State Cow of the Year award at the 2014 World Dairy Expo on Oct. 3 was only the second biggest thing that happened while the Peterson family of Cashton was in Madison that week.

The most important came a few days later, on the west side of the University of Wisconsin-Madison campus, when stem cells from Kurt Petersons bone marrow began flowing into the blood stream of his brother, giving Scot Peterson, 45, a new immune system and a good shot of beating adult acute lymphoblastic leukemia (ALL).

Hes a man of few words, says Scot, of his younger brother, Kurt, 40. But you know he really loves you to do something like this.

Its been a good news/bad news kind of a year for the Peterson brothers, who co-own the Coulee Crest farm in the rolling hills of Monroe County, and the states queen of cows, Coulee Crest Nick Lorilyn. Guernseys are the caramel brown and white cows known for the richness of their milk. And Lorilynn won the crown because she, her mother, and one of her daughters have each produced 40,000 pounds of milk in a year.

The last weekend in June, the National Guernsey Association held its national convention in La Crosse. The Petersons hosted a tour of their farm and a dinner event for 475 convention goers at their farm.

Scot Peterson, a burly guy who competed in Sweden for the world tug-of-war championship when he was younger, felt pains in his legs, odd bruises, and general exhaustion.

I thought I was tired from all the work of getting the farm ready, Scot Peterson says. He got through the convention and the national sale on June 30. That was another high point for the farm, with one of Lorilyns daughters topping the sale at $19,000.

By the next day, there was bad news.

By the middle of the day on July 1, I was in the hospital, finding out my diagnosis of leukemia, he recalls.

His oncologist, Dr. Wayne Bottner of Gundersen Health System in La Crosse, told Scot that he had a type of leukemia, ALL, in which the bone marrow makes too many lymphocytes, a type of white blood cell. ALL is more common and easier to treat in children. Adults fare better if they can find a match that allows them to have a stem cell transplant from a donors bone marrow. So Bottner referred Peterson to the UW Carbone Comprehensive Cancer Center in Madison.

Originally posted here:
Cashton man goes from winning state award to battling cancer

Contact Information

Available for logged-in reporters only

Newswise Four scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received a National Institutes of Health (NIH) Director's New Innovator Award that will forward revolutionary stem cell and neuro-science in medicine. The four UCLA researchers were among only 50 scientists nationwide to receive the New Innovator Award, the most of any institution represented.

Each recipient received a $2.3M award for their respective projects. These included Dr. Reza Ardehali, assistant professor of cardiology, for his research investigating novel ways to use stem cells to regenerate heart tissue; Dr. Elissa Hallem, assistant professor of microbiology, immunology and molecular genetics, for her work studying interactions between animal parasites and their hosts to foster the further understanding of human parasitic diseases; Dr. Sririam Kosuri, assistant professor of chemistry and biochemistry, for his project developing new biological system technologies to solve outstanding problems in gene regulation; and Dr. Lili Yang, assistant professor of microbiology, immunology and molecular genetics, for her work developing a new method to track special immune cells for use in new cellular therapies.

"These New Innovator Award grants are an important acknowledgement of our cutting-edge research and will help our faculty drive the revolutionary advances we are seeing in stem cell and neuro-science," said Dr. Owen Witte, professor and director of the Broad Stem Cell Research Center. "Every cellular therapy that reaches patients must begin in the laboratory with novel ideas and experiments that will lead us in new directions in medicine and ultimately improve human life. That makes these awards invaluable to our research effort."

The NIH Director'sNew Innovator Award is designed specifically to support unusually creative investigators with highly innovative research ideas at an early stage of their career. The award seeks to support exceptionally creative new scientists whose research complements ongoing efforts by NIH.

Dr. Reza Ardehali: Unlocking the Secrets to Regenerating Heart Tissue

Dr. Ardehali's cutting-edge work focuses on both human embryonic stem cells and induced pluripotent stem cells, known as human pluripotent stem cells (hPSC), to provide insights into the mechanisms involved in the differentiation and specification of heart cells. hPSC have the unique ability to become any cell type in the body. His lab recently identified several novel surface markers that can highly enrich early cardiovascular progenitor cells. When delivered into functioning human hearts that are transplanted in laboratory conditions, the progenitor cells integrate structurally and functionally into the host myocardium. These studies established the basis for future hPSC-based cardiac therapy.

Dr. Ardehali and his colleagues were also the first to directly measure limited division in the cells that make up heart muscle (cardiomyocytes), proving that cardiomyocytes divide and that such cell division is rare. This discovery resolves an important controversy over whether the heart muscle has the power to regenerate and is critical for future research that may lead to regenerating heart tissue to repair damage caused by disease or heart attack.

His 2013, California Institute for Regenerative Medicine (CIRM), the state's stem cell research agency, New Faculty Physician Scientist Translational Research Award allowed Dr. Ardehali to initiate the preclinical studies on stem cell based therapies for heart disease that were pivotal for his success in the 2014 New Innovator Award competition. The NIH grant affirms the critical success of the project-to-date, and emphasizes the creativity of Dr. Ardehali's research and its potential to have a significant impact on the creation of novel regenerative approaches to treat heart disease.

Excerpt from:
Four UCLA Scientists Receive Prestigious Innovator Award for Pioneering Research Using Stem Cells

96 Year Old Women gets Stem Cell Therapy
96 Year Old Women who suffered from Osteoarthritis uses Stem Cells and no longer needs to use her walker. Dr. Lox | http://www.drloxstemcells.com | 844-440-8503.

By: Dr. Lox

Read the original:
96 Year Old Women gets Stem Cell Therapy - Video

Learn How Stem Cell Therapy Is Being Used Right Here in North Texas
http://www.innovationsstemcellcenter.com Call: 214.420.7970 Facebook: https://www.facebook.com/innovationsmedical Twitter: https://twitter.com/dallasdrj Instagram: http://instagram.com/drbilljo...

By: dallasdrj

Read more here:
Learn How Stem Cell Therapy Is Being Used Right Here in North Texas - Video

Can brain damage caused during birth be ever reversed? Is it possible to repair the damaged brain tissues among children, who suffer from Cerebral Palsy (CP)?

So far, the treatment option for CP is to manage the symptoms of the ailment. However, in recent times, scientists and researchers worldwide have started to explore stem cell therapy as a potential treatment option for CP patients.

Can stem cells reverse the brain damage, which is the sole cause for CP among children? Our research on over 100 CP patients and stem cell therapy has been very encouraging. The patients, who underwent stem cell therapy, have displayed huge improvement in CP symptoms, says Professor and Head of Neurosurgery, LTM Medical College, Mumbai, Alok Sharma.

The neurosurgeon, who is taking part in an international conference on CP in Hyderabad this weekend, said that doctors are not concentrating on treating the brain damage.

The current treatment options available to help patients are only to mange symptoms and nobody tries to repair the underlying damage to the brain tissue. Therefore, developing a standard therapeutic approach for CP through stem cells is the need of the hour, he said.

The results from the stem cell therapy on CP patients conducted by Dr. Aloks team were recently published in Neurogens chapter on Stem cell therapy for cerebral palsy A Novel Option in a book titled Cerebral Palsy Challenges For the Future. According to the neurosurgeon, the patients after therapy had improvements in their speech, balance, upper and lower limb activity and movement.

While for stem cell research, many prefer cord blood banking, Dr. Alok pointed out that they have used stem cells from the adults derived from the bone marrow. The transplanted stem cells have the ability to migrate to the area of the damaged tissue in the brain and home-in on those affected areas to help repair the damage. Stem cells release substance that stimulates natural growth, which decreases the process of damage of the brain, Dr. Alok explained.

The researcher, who has started NeuroGen Brain and Spine Institute in Mumbai to conduct stem cell research, pointed out that stem cell therapy and other rehabilitation programmes should be encouraged for the benefit of CP patients. The positive changes that we recorded in our patients were not just restricted to their symptoms but also constructive change in brain metabolism observed through PET-CT scans, he explained. Dr. Alok Sharma can be reached at: alok276@gmail.com

Read the original:
Fighting CP through stem cell therapy

10.10.2014 - (idw) Fraunhofer-Gesellschaft

From 9-10 October 2014 around 200 scientists met at the Leipzig Fraunhofer Institute for Cell Therapy and Immunology for the ninth Fraunhofer Life Science Symposium. Held every two years, this year the event focused on the theme "Medicinal Cell Products and Stem Cells for Medicinal Applications". In recent years biomedical research has revealed numerous promising new approaches for the prevention and treatment of serious illnesses. The issue of stem cells plays a key role in this. With the symposium the Fraunhofer IZI offers international scientists a platform on which they can discuss the latest developments in this field.

The scientific program encompasses three major subject areas: production, manufacture and application. In the first section a paper presented by Sarah Ferber (Centre for Stem Cells, Regenerative Medicine and Tissue Engineering, Sheba Medical Center, Tel Hashomer, Israel) was one major point of interest: "Reprogramming the endocrine pancreas; autologous cell replacement therapy for diabetic patients". She spoke about the possibilities for transforming liver cells into insulin-producing cells. In the future this method could possibly be used to help patients with type 1 diabetes, where the misdirected immune system destroys the body's own insulin-producing beta cells of the pancreas.

The Fraunhofer Life Science Symposium brings together up to 200 participants from academic and clinical institutions to discuss the various focal points concerning new technologies, trends and developments. It is organized by the Fraunhofer Institute for Cell Therapy and Immunology IZI. For further information see http://www.fs-leipzig.com. Weitere Informationen:http://www.fs-leipzig.comhttp://www.izi.fraunhofer.de

More here:
Experts discuss new developments in the field of stem cell research and cell therapy

Ageless Derma Apple Stem Cell Skincare
This active ingredient won the Best Active Ingredient prize in European Innovation in 2008. Stem Cells derived from a rare Swiss Apple are part of the rev...

By: Rokshana popal

See original here:
Ageless Derma Apple Stem Cell Skincare - Video

CAMBRIDGE, Mass., Oct. 9 (UPI) -- Patients with type 1 diabetes lack the insulin-producing cells that keep blood glucose levels in check. Currently, these patients must use insulin pumps or daily hormone injections to keep levels stable.

But in a recent breakthrough in laboratories at Harvard University, researchers came upon a new technique for transforming stem cells into pancreatic beta cells that respond to glucose levels and produce insulin when necessary. The breakthrough could lead to new less invasive, more hands-off treatment for diabetes.

Remarkably, the new technique -- a complex process which involves turning on and off specific genes and takes about 40 days and six precise steps to complete -- was replicated not only on embryonic stem cells but also on human skin cells reprogrammed to act in a stem-cell-like manner. This revelation allows scientists to produce millions of insulin-producing cells while avoiding the ethical dilemmas attached to traditional stem cell research.

Previous attempts to convert stem cells into insulin-producers have proven moderately successful, but these cells mostly produced insulin at will, unable to adjust their output on the fly. The latest techniques -- developed by Douglas Melton, co-director of the Harvard Stem Cell Institute, and his research colleagues -- produce insulin cells that react to glucose spikes by upping production, and lowering insulin output when there's not excess sugar to break down.

The breakthrough has already shown significant promise when used on lab mice. Diabetic mice who received a transplant of the stem cell beta cells had improved blood sugar levels, and were shown to be capable of breaking down sugar.

"We can cure their diabetes right away -- in less than 10 days," Melton told NPR. "This finding provides a kind of unprecedented cell source that could be used for cell transplantation therapy in diabetes."

But there's still one major issue. For reasons doctors still don't understand, the beta cells in humans with diabetes are attacked by the body's immune system. Researchers like Melton still have to figure out a way to protect the new beta cells from being killed -- otherwise the breakthrough won't become anything more than another short-term solution.

"It's taken me 10 to 15 years to get to this point, and I consider this a major step forward," Melton told TIME. "But the longer term plan includes finding ways to protect these cells, and we haven't solved that problem yet."

2014 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.

More here:
Harvard researchers grow insulin-producing stem cells

October 10, 2014 - 17:56 AMT

PanARMENIAN.Net - In what could be a major breakthrough for diabetes treatment, scientists have discovered a way to drastically alter human embryonic stem cells, transforming them into cells that produce and release insulin, RT said.

Developed by researchers at Harvard University, the innovative new technique involves essentially recreating the formation process of beta cells, which are located in the pancreas and secrete insulin. By stimulating certain genes in a certain order, the Boston Globe reports that scientists were able to charm embryonic stem cells and even altered skin cells into becoming beta cells.

The whole process took 15 years of work, but now lead researcher Doug Melton says the team can create hundreds of millions of these makeshift beta cells, and theyre hoping to transplant them into humans starting in the next few years.

"We are reporting the ability to make hundreds of millions of cells the cell that can read the amount of sugar in the blood which appears following a meal and then squirts out or secretes just the right amount of insulin," Melton told NPR.

There are 29.1 million people in the United States believed to have diabetes, according to statistics by the Centers for Disease Control and Prevention dating back to 2012. Thats 9.3 percent of the entire population.

Currently, diabetes patients must rely on insulin shots to keep their blood-sugar levels stable, a process that involves continual monitoring and attentiveness. Failure to efficiently control these levels can cause some patients to go blind, suffer from nerve damage and heart attacks, and even lose limbs. If Meltons beta cell creation process can be successfully applied to humans, it could eliminate the need for such constant check-ups, since the cells would be doing all the monitoring. Already, there are positive signs moving forward: the transplanted cells have worked wonders on mice, quickly stabilizing their insulin levels.

"We can cure their diabetes right away in less than 10 days," Melton said to NPR. "This finding provides a kind of unprecedented cell source that could be used for cell transplantation therapy in diabetes."

With mice successfully treated, the team is now working with a scientist in Chicago to put cells into primates, the Globe reported.

Even so, significant obstacles remain, particularly for those who have Type 1 diabetes. With this particular form of the disease, the human immune system actually targets and destroys insulin-producing beta cells in the pancreas, so Meltons team is looking into encasing cells inside of a protective shell in order to ensure their safety.

Read the rest here:
Harvard University scientists alter stem cells to make insulin

Research into a cure for diabetescould result in an end to insulin injections It has beenhailed as the biggest medical breakthrough since antibiotics Harvard researcher Doug Melton promised his children he'd find a cure Treatment involves making insulin-producing cells from stem cells Scientistshope to have human trials under way within a 'few years'

By Fiona Macrae for the Daily Mail

Published: 17:41 EST, 9 October 2014 | Updated: 04:45 EST, 10 October 2014

1.7k shares

152

View comments

Scientists have hailed stem-cell research into a cure for diabetes as potentially the biggest medical breakthrough since antibiotics.

It could result in an end to insulin injections, and to the disabling and deadly complications of the disease, such as strokes and heart attacks, blindness and kidney disease.

The treatment, which involves making insulin-producing cells from stem cells, was described as a 'phenomenal accomplishment' that will 'leave a dent in the history of diabetes'.

Scroll down for video

More:
Could this stem cell breakthrough offer an end to diabetes?

StemCells Inc. ( STEM ) announced that it has commenced a phase II proof-of-concept study, Pathway, which will use the company's proprietary human neural system stem cells (HuCNS-SC) platform for treating patients suffering from cervical spinal cord injury (SCI). The company's phase II trial is titled "Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury."

The randomized, controlled, single-blind study will evaluate the safety and efficacy of transplanting HuCNS-SC cells into patients with traumatic injury in the cervical region of the spinal cord. The study will evaluate patients for a period of 12 months post-enrollment.

We remind investors that earlier in the year, the company had reported encouraging interim results from a phase I/II thoracic SCI study. StemCells intends to present final data from the phase I/II study in mid-2015.

According to the press release issued by StemCells, nearly 1.3 million people in the U.S. have reported paralysis due to an SCI and about 56% of spinal cord injuries occur in the cervical region. Upon approval, the new treatment will provide significant benefits to patients suffering from cervical SCI considering the present lack of effective treatments.

Meanwhile, StemCells is currently evaluating HuCNS-SC cells for several other indications including dry age-related macular degeneration (AMD), Pelizeaus-Merzbacher disease (PMD) and Alzheimer's disease.

We expect investor focus to remain on pipeline updates.

StemCells currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Emergent BioSolutions, Inc. ( EBS ), Ligand Pharmaceuticals Inc. ( LGND ) and Medivation, Inc. ( MDVN ). All three carry a Zacks Rank #1 (Strong Buy).

STEMCELLS INC (STEM): Get Free Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

LIGAND PHARMA-B (LGND): Free Stock Analysis Report

Read the rest here:
StemCells Starts Phase II Cervical Spinal Cord Injury Study - Analyst Blog

October 8, 2014

Image Caption: New genetic barcoding technology allows scientists to identify differences in origin between individual blood cells. Credit: Camargo Lab

Provided by Joseph Caputo, Harvard University

New technology that tracks the origin of blood cells challenges scientific dogma

A 7-year-project to develop a barcoding and tracking system for tissue stem cells has revealed previously unrecognized features of normal blood production: New data from Harvard Stem Cell Institute scientists at Boston Childrens Hospital suggests, surprisingly, that the billions of blood cells that we produce each day are made not by blood stem cells, but rather their less pluripotent descendants, called progenitor cells. The researchers hypothesize that blood comes from stable populations of different long-lived progenitor cells that are responsible for giving rise to specific blood cell types, while blood stem cells likely act as essential reserves.

The work, supported by a National Institutes of Health Directors New Innovator Award and published in Nature, suggests that progenitor cells could potentially be just as valuable as blood stem cells for blood regeneration therapies.

This new research challenges what textbooks have long read: That blood stem cells maintain the day-to-day renewal of blood, a conclusion drawn from their importance in re-establishing blood cell populations after bone marrow transplantsa fact that still remains true. But because of a lack of tools to study how blood forms in a normal context, nobody had been able to track the origin of blood cells without doing a transplant.

Boston Childrens Hospital scientist Fernando Camargo, PhD, and his postdoctoral fellow Jianlong Sun, PhD, addressed this problem with a tool that generates a unique barcode in the DNA of all blood stem cells and their progenitor cells in a mouse. When a tagged cell divides, all of its descendant cells possess the same barcode. This biological inventory system makes it possible to determine the number of stem cells/progenitors being used to make blood and how long they live, as well as answer fundamental questions about where individual blood cells come from.

Theres never been such a robust experimental method that could allow people to look at lineage relationships between mature cell types in the body without doing transplantation, Sun said. One of the major directions we can now go is to revisit the entire blood cell hierarchy and see how the current knowledge holds true when we use this internal labeling system.

People have tried using viruses to tag blood cells in the past, but the cells needed to be taken out of the body, infected, and re-transplanted, which raised a number of issues, said Camargo, who is a member of Childrens Stem Cell Program and an associate professor in Harvard Universitys Department of Stem Cell and Regenerative Biology. I wanted to figure out a way to label blood cells inside of the body, and the best idea I had was to use mobile genetic elements called transposons.

Read more:
Scientists Develop Barcoding Tool For Stem Cells

Ageless Derma Anti Aging Skin Care
This active ingredient won the Best Active Ingredient prize in European Innovation in 2008. Stem Cells derived from a rare Swiss Apple are part of the revolutionary technological designed...

By: Rokshana popal

Read more from the original source:
Ageless Derma Anti Aging Skin Care - Video

Hamish Gilbert - Development of a Stem Cell Therapy forRepair of the Degenerate Intervertebral Disc
Description.

By: FMHSGraduateSociety

More:
Hamish Gilbert - Development of a Stem Cell Therapy forRepair of the Degenerate Intervertebral Disc - Video

Arthritis of shoulder; results four years after stem cell therapy by Harry Adelson, N.D.
Heavy discusses his outcome four years out from his first bone marrow stem cell treatment for his arthritic shoulders and torn rotator cuffs by Harry Adelson, N.D. http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read the rest here:
Arthritis of shoulder; results four years after stem cell therapy by Harry Adelson, N.D. - Video

Michael Scott, a ViaCyte vice president, holds the VC-01 device that holds progenitor cells that will mature to make insulin and other hormones.

More than ever before, stem cell therapies appear poised to transform medicine potentially curing heart disease, diabetes and paralyzing injuries, among other ailments.

But its also clear that such innovations will be very expensive.

How the government, insurers and patients will pay for what could be a flood of these new treatments drew the attention of more than 700 biomedical and health-care executives Tuesday at the 2014 Stem Cell Meeting on the Mesa.

The annual conference, held on La Jolla's Torrey Pines Mesa, will run through Thursday. It brings together the business and academic worlds of cell therapy, including but not limited to stem cell treatments.

In California alone, 131 clinical trials are taking place with stem cells, according to Clinicaltrials.gov, a government website that tracks clinical trials. Patients are being treated for conditions such as blindness from retinal diseases, HIV, leukemia, sickle cell disease, stroke and aging of skin.

The recent proliferation of clinical trials marks great progress toward the ultimate goal of getting new treatments to patients, said stem cell researcher Jeanne Loring, who directs the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla.

Its been a sea change from last year, said Loring, who is working with some colleagues in planning their own stem cell trial to treat Parkinsons disease.

Theyre developing replacement neurons grown from artificial embryonic stem cells called induced pluripotent stem cells. The process begins with cells derived from the skin of patients to be treated.

Home-grown milestone

Go here to see the original:
Stem cell treatments surging into clinic

A combined LifeSource blood drive and Be The Match bone marrow registry event will honor two local women battling different forms of leukemia from 8 a.m. to 2 p.m. Saturday, Oct. 11, at The Society of Danube Swabians, 625 E. Seegers Road, Des Plaines.

The event will co-honor Des Plaines resident Amy Charewicz, 24, and Prospect Heights resident Anni Mayer, who is a Society of Danube Swabians board member. Mayer, a St. Alphonsus Ligouri parishioner and national society youth group leader, has Myelodyplastic Syndrome, a blood cancer that prevents her bone marrow from making enough healthy blood cells. Charewicz has aggressive Acute Myeloblastic Leukemia, a disease that causes her bone marrow to produce abnormal white and red blood cells, as well as platelets.

The Northern Illinois University graduate will receive a stem cell transplant Thursday from a 23-year-old man located by Be the Match at Northwestern Memorial Hospital. "Amy has been fortunate to have what she needs available because others have donated and registered," says Doris Charewicz, her mother. "She wants to 'pay it forward' by increasing awareness of the need for both blood donors and stem cell donors."

Be The Match registrants are limited to ages 18-44 and don't need to preregister. Blood donor walk-ins are welcome, but appointments are preferred at (877) 543-3768 or http://www.lifesource.org using code 650B.

View post:
Bone marrow registry drive Saturday in Des Plaines

Henderson, NV (PRWEB) October 07, 2014

Stem cells from plants are becoming an increasingly popular way to turn the clock backward on skin aging. Hylunia's own light and silky Moisure Infusion contains plant stem cells and peptides that are thought to delay aging, making skin look softer smoother and younger.

Plant stem cells like the ones found in grapes are undifferentiated cells from the meristems of plants. Like human stem cells, they can replace damaged cells and renew themselves. Plant stem cells are cultured in labs, allowing scientists to have more control over the quality, quantity and purity of a plant's anti-aging substance.

Skin care stem cells are extracted from various plants, including tiny white Edelweiss flowers, a swamp plant called gotu kola, swiss apples, and raspberry cell cultures. Lilac and algae may also be used. Most of these products contain antioxidants and other chemicals that make skin look younger.

Hylunia's unique product features grape stem cells cultivated from the Gamay Teinturier Fraux grape from Burgundy, France. Their ingredient list explains that these grapes are "high in powerful antioxidants and [have] free radical scavenging capabilities."

The site adds that "The Grape Stem Cells contain special epigenetic factors and metabolites which are able to protect human stem cells against UV radiation and therefore delay aging." UV damage is responsible for up to 80% of skin aging.

Hylunia Moisture Infusion also contains peptides, which can boost collagen and block the neurotransmitters that contract the muscles that form wrinkles. They stimulate epidermal skin cells and increase skin healing and repair.

Hyluna's product contains Palmitoyl Trypeptide-5 (patented), which stimulates collagen synthesis to "strengthen skin and reduce the appearance of fine lines and wrinkles."

Hylunia is currently putting together a webinar about plant peptides for their professional customers like spa and salon owners. The webinar will be available soon.

Read the original:
Hylunia Educates Professional Customers on Anti-Aging Peptides and Stem Cells